Pricing Log in Create free account

Allogene Therapeutics, Inc. (ALLO) vs Monopar Therapeutics Inc. (MNPR)

Allogene Therapeutics, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Monopar Therapeutics Inc. are of similar size ($481.9M and $463.0M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −3,517.4%) and the higher return on invested capital (0.00% vs −108.8%). Across the 12 metrics below, Monopar Therapeutics Inc. leads on 10 and Allogene Therapeutics, Inc. on 2.

Valuation

Metric ALLO MNPR Biotechnology median
P/E n/m n/m 8.50
P/S 91.58 n/m 9.71
P/B 0.99 4.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 20.89 n/m 9.21
Earnings yield (51.15%) (3.13%) (33.15%)
Free cash flow yield (23.81%) (2.06%) (25.50%)

Profitability

Metric ALLO MNPR Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (3,832.45%) 0.00% 0.00%
Net margin (3,517.41%) 0.00% 0.00%
Free cash flow margin (2,180.62%) 0.00% 0.00%
Return on equity (42.39%) (19.50%) (56.36%)
Return on assets (32.43%) (18.90%) (48.04%)
Return on invested capital (108.81%) 0.00% 0.00%

Growth

Metric ALLO MNPR Biotechnology median
Revenue growth (TTM) 7,613.11% — 6.02%
EPS growth (last fiscal year) 34.09% 54.99% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALLO MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.72 33.56 4.72
Net debt to EBITDA 1.24 8.06 0.96

Dividend

Metric ALLO MNPR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALLO MNPR Biotechnology median
Market cap 462.96m 481.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack